Patel H, Macarthur C, Johnson D
Division of General Pediatrics, Hospital for Sick Children, University of Toronto, Ontario.
Arch Pediatr Adolesc Med. 1996 Apr;150(4):409-14. doi: 10.1001/archpedi.1996.02170290075012.
To determine whether recent corticosteroid use was associated with an increased risk of complicated varicella-zoster virus infection in otherwise immunocompetent children.
A case-control study design was used because the outcome of interest, complicated varicella-zoster virus infection, is rare.
Cases and controls were selected from the population of children aged 2 months to 18 years admitted to two hospitals, between January 1979 and July 1994 in one and between January 1974 and July 1994 in the other, with diagnosis codes that indicated chickenpox.
Cases were defined as children with invasive varicella-zoster virus infection or associated invasive bacterial infection. Controls were defined as children with uncomplicated varicella admitted for elective surgery, fracture or burn management, psychiatric or social evaluation, treatment of simple dehydration, or evaluation of fever or rash not yet diagnosed. Exclusions included varicella-zoster virus infection in neonates and immunocompromised children.
A priori criteria were formulated on the basis of a comprehensive literature review to define complicated varicella-zoster virus infection. Recent corticosteroid exposure was defined as corticosteroid use of any sort within 30 days of onset of the chickenpox rash. Data were abstracted by medical chart review.
In total, 167 cases and 134 controls were identified. Only three children (two cases and one control) had a history of recent corticosteroid therapy. Recent corticosteroid exposure was therefore not statistically associated with an increased risk of complicated varicella-zoster virus infection (odds ratio, 1.6; 95% confidence interval, 0.2 to 16.9). No differences between cases and controls were found in sex, history of asthma, or length of hospital stay. The mean age of cases was greater than that of controls (6.0 vs 4.7 years; P<.01).
Recent corticosteroid therapy in otherwise immunocompetent children does not appear to be associated with a statistically increased risk of complicated varicella. A conservative estimate of risk, using the upper limit of the 95% confidence interval, is markedly lower than previously published risk estimates.
确定近期使用皮质类固醇激素是否会增加原本免疫功能正常的儿童发生水痘 - 带状疱疹病毒感染并发症的风险。
采用病例对照研究设计,因为所关注的结局——水痘 - 带状疱疹病毒感染并发症较为罕见。
病例和对照选自1979年1月至1994年7月期间在一家医院以及1974年1月至1994年7月期间在另一家医院收治的2个月至18岁儿童,其诊断编码显示为水痘。
病例定义为患有侵袭性水痘 - 带状疱疹病毒感染或相关侵袭性细菌感染的儿童。对照定义为因择期手术、骨折或烧伤处理、精神或社会评估、单纯脱水治疗或未确诊的发热或皮疹评估而入院治疗的无并发症水痘儿童。排除新生儿和免疫功能低下儿童的水痘 - 带状疱疹病毒感染。
基于全面的文献综述制定了先验标准,以定义水痘 - 带状疱疹病毒感染并发症。近期皮质类固醇激素暴露定义为水痘皮疹出现后30天内使用过任何类型的皮质类固醇激素。通过查阅病历提取数据。
共确定了167例病例和134例对照。只有3名儿童(2例病例和1例对照)有近期皮质类固醇激素治疗史。因此,近期皮质类固醇激素暴露与水痘 - 带状疱疹病毒感染并发症风险增加在统计学上无关联(比值比为1.6;95%置信区间为0.2至16.9)。病例和对照在性别、哮喘病史或住院时间方面未发现差异。病例的平均年龄大于对照(6.0岁对4.7岁;P<0.01)。
原本免疫功能正常的儿童近期使用皮质类固醇激素治疗似乎与水痘并发症风险在统计学上增加无关。使用95%置信区间上限对风险进行的保守估计明显低于先前公布的风险估计值。